Better understanding of γδT cell biology and stratifying healthy donors for allogeneic adoptive therapy is clinically needed to fully realize the therapeutic potential of γδT cells. We examine 98 blood samples from healthy donors and measure their expansion capacity, migration and cytotoxic effector function after zoledronate stimulation. We find that basal γδT cell levels in PBMC correlate well with their expansion, migration and cytotoxic effector capacity in vitro. A cut-off level of 0.82% γδT cells in PBMC stratifies good versus poor γδT cell expansion in healthy individuals. Donors with higher Vδ2 Index Score in PBMC have greater anti-tumor functions. Examination of circulating γδT cell level may be used to select healthy donors to participate γδT-based immunotherapies.

LinglingOu1,2, HuaishanWang1, Qin Liu3, JieZhang9, HezheLu10,11, LiangpingLuo2, ChangzhengShi2, ShaoqiangLin8, LiyunDong1, YeyeGuo1, Lili Huang1,
JinjinZhu1, Xiangfan Yin3, Alexander C. Huang4, GiorgosKarakousis5, Lynn Schuchter4, Ravi Amaravadi4, Cathy Zheng4, Yi Fan6, Wei Guo7, XiaoweiXu1

1 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

2 Department of Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, P.R. China